{"id":"NCT00781937","sponsor":"Novo Nordisk A/S","briefTitle":"Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance","officialTitle":"Effect of Liraglutide on Long-term Weight Maintenance and Additional Weight Loss Induced by a 4 to 12 Week Low Calorie Diet in Obese Subjects; A 56 Week Randomised, Double-blind, Placebo Controlled, Parallel Group, Multicentre Trial With a 12 Week Follow-up Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-30","primaryCompletion":"2010-09-01","completion":"2010-09-01","firstPosted":"2008-10-29","resultsPosted":"2011-11-28","lastUpdate":"2017-11-01"},"enrollment":422,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metabolism and Nutrition Disorder","Obesity"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Lira 3.0 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood).\n\nTrial has following trial periods: A 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68).","primaryOutcome":{"measure":"Mean Percentage Change in Fasting Body Weight From Baseline","timeFrame":"Week 0, week 56","effectByArm":[{"arm":"Lira 3.0 mg","deltaMin":-6.11,"sd":0.66},{"arm":"Placebo","deltaMin":-0.05,"sd":0.63}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":37,"countries":["United States","Canada"]},"refs":{"pmids":["27482610","27817208","23812094","26418188","28473337","28386912","28950422"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":212},"commonTop":["Nausea","Nasopharyngitis","Constipation","Diarrhoea","Headache"]}}